SCHEMBL3075932

SCHEMBL3075932

COC(=O)[C@H]1c2ccc(OCc3ccc(OC)cc3)cc2CCN1C(=O)OC(C)(C)C

nearest known ligand 0.63

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 15/20 0.63
MMP1 P03956 1/20 0.51
MMP2 P08253 1/20 0.51
MMP7 P09237 1/20 0.51
MMP9 P14780 1/20 0.51
MMP12 P39900 1/20 0.51
MMP14 P50281 1/20 0.51
MMP15 P51511 1/20 0.51
MMP16 P51512 1/20 0.51
MMP26 Q9NRE1 1/20 0.51
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3075509 0.94 GHSR (0.62) GHSRMMP1MMP2MMP7MMP9
SCHEMBL3071277 0.94 GHSR (0.60) GHSRMMP1MMP2MMP7MMP9
SCHEMBL3067854 0.93 GHSR (0.61) GHSRMMP1MMP2MMP7MMP9
SCHEMBL3076015 0.93 GHSR (0.61) GHSR
SCHEMBL3069228 0.93 GHSR (0.61) GHSRMMP2MMP9MMP12MMP14
SCHEMBL3072399 0.93 GHSR (0.59) GHSRCYP3A4CYP2D6CYP2C19
SCHEMBL14862864 0.93 GHSR (0.73) GHSRMMP1MMP2MMP7MMP9
SCHEMBL7120537 0.93 GHSR (0.73) GHSRMMP1MMP2MMP7MMP9
SCHEMBL3072393 0.93 GHSR (0.73) GHSRMMP1MMP2MMP7MMP9
SCHEMBL3066630 0.92 GHSR (0.62) GHSRMMP1MMP2MMP7MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951675-B1 TETRAHYDROISOQUINOLINE AS LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-03-20 EP disclosed
EP-1951675-B1 TETRAHYDROISOQUINOLINE AS LXR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-03-20 EP disclosed
US-7790745-B2 Tetrahydroisoquinoline LXR Modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 US disclosed
US-7790745-B2 Tetrahydroisoquinoline LXR Modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 US disclosed
US-7790745-B2 Tetrahydroisoquinoline LXR Modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 US disclosed
WO-2007047991-A1 TETRAHYDROISOQUINOLINE AS LXR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-26 WO disclosed
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators BRISTOL-MYERS SQUIBB COMPANY 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093523-A1 Tetrahydroisoquinoline LXR modulators NR1H2, NR1H3, NR1I2 GHSR 351/4885MMP1 4870/4885MMP2 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.